U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Breast Neuroendocrine Tumor G2

MedGen UID:
1786564
•Concept ID:
C5446660
•
Neoplastic Process

Definition

A well-differentiated, intermediate grade neuroendocrine neoplasm arising from the breast. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVBreast Neuroendocrine Tumor G2

Professional guidelines

PubMed

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE, Zhernosekov K
Front Endocrinol (Lausanne) 2022;13:941832. Epub 2022 Oct 31 doi: 10.3389/fendo.2022.941832. PMID: 36387893Free PMC Article
Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall.
Vyas M, Tang LH, Rekhtman N, Klimstra DS
Am J Surg Pathol 2021 Jan;45(1):25-34. doi: 10.1097/PAS.0000000000001602. PMID: 33177340Free PMC Article
Radio hyperthermia for re-treatment of superficial tumours.
Gabriele P, Ferrara T, Baiotto B, Garibaldi E, Marini PG, Penduzzu G, Giovannini V, Bardati F, Guiot C
Int J Hyperthermia 2009 May;25(3):189-98. doi: 10.1080/02656730802669593. PMID: 19212860

Recent clinical studies

Etiology

Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, Miki M, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y
J Gastroenterol 2023 Jun;58(6):586-597. Epub 2023 Apr 26 doi: 10.1007/s00535-023-01987-8. PMID: 37099152
Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcome.
Metovic J, Cascardi E, Uccella S, Maragliano R, Querzoli G, Osella-Abate S, Pittaro A, La Rosa S, Bogina G, Cassoni P, Marchiò C, Sapino A, Castellano I, Papotti M
Virchows Arch 2022 Dec;481(6):839-846. Epub 2022 Oct 15 doi: 10.1007/s00428-022-03426-0. PMID: 36243799Free PMC Article
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E, Kjellman M, Knigge U, Gronbaek H, Schalin-Jäntti C, Welin S, Sorbye H, Del Pilar Schneider M, Belusa R; Nordic NET Biomarker Group
J Neuroendocrinol 2022 Jul;34(7):e13176. Epub 2022 Jul 13 doi: 10.1111/jne.13176. PMID: 35829662Free PMC Article
Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J, Bjellerup-Calissendorff F, Bränström R, Juhlin CC, Falhammar H
Front Endocrinol (Lausanne) 2021;12:657698. Epub 2021 Apr 13 doi: 10.3389/fendo.2021.657698. PMID: 33927695Free PMC Article
Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells.
Čáňová K, Rozkydalová L, Vokurková D, Rudolf E
Toxicol In Vitro 2018 Feb;46:313-322. Epub 2017 Oct 26 doi: 10.1016/j.tiv.2017.10.025. PMID: 29107018

Diagnosis

The Approach of Artificial Intelligence in Neuroendocrine Carcinomas of the Breast: A Next Step towards Precision Pathology?-A Case Report and Review of the Literature.
Chiorean DM, Mitranovici MI, Mureșan MC, Buicu CF, Moraru R, Moraru L, Cotoi TC, Cotoi OS, Apostol A, Turdean SG, Mărginean C, Petre I, Oală IE, Simon-Szabo Z, Ivan V, Roșca AN, Toru HS
Medicina (Kaunas) 2023 Mar 28;59(4) doi: 10.3390/medicina59040672. PMID: 37109630Free PMC Article
Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, Miki M, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y
J Gastroenterol 2023 Jun;58(6):586-597. Epub 2023 Apr 26 doi: 10.1007/s00535-023-01987-8. PMID: 37099152
Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcome.
Metovic J, Cascardi E, Uccella S, Maragliano R, Querzoli G, Osella-Abate S, Pittaro A, La Rosa S, Bogina G, Cassoni P, Marchiò C, Sapino A, Castellano I, Papotti M
Virchows Arch 2022 Dec;481(6):839-846. Epub 2022 Oct 15 doi: 10.1007/s00428-022-03426-0. PMID: 36243799Free PMC Article
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E, Kjellman M, Knigge U, Gronbaek H, Schalin-Jäntti C, Welin S, Sorbye H, Del Pilar Schneider M, Belusa R; Nordic NET Biomarker Group
J Neuroendocrinol 2022 Jul;34(7):e13176. Epub 2022 Jul 13 doi: 10.1111/jne.13176. PMID: 35829662Free PMC Article
Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J, Bjellerup-Calissendorff F, Bränström R, Juhlin CC, Falhammar H
Front Endocrinol (Lausanne) 2021;12:657698. Epub 2021 Apr 13 doi: 10.3389/fendo.2021.657698. PMID: 33927695Free PMC Article

Therapy

TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING.
Bharti V, Kumar A, Wang Y, Roychowdhury N, de Lima Bellan D, Kassaye BB, Watkins R, Capece M, Chung CG, Hilinski G, Vilgelm AE
JCI Insight 2024 Jun 20;9(15) doi: 10.1172/jci.insight.177523. PMID: 38900577
Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, Miki M, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y
J Gastroenterol 2023 Jun;58(6):586-597. Epub 2023 Apr 26 doi: 10.1007/s00535-023-01987-8. PMID: 37099152
SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
Deng S, Banerjee S, Chen H, Pochampally S, Wang Y, Yun MK, White SW, Parmar K, Meibohm B, Hartman KL, Wu Z, Miller DD, Li W
Cancer Lett 2023 Feb 28;555:216046. Epub 2022 Dec 31 doi: 10.1016/j.canlet.2022.216046. PMID: 36596380Free PMC Article
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE, Zhernosekov K
Front Endocrinol (Lausanne) 2022;13:941832. Epub 2022 Oct 31 doi: 10.3389/fendo.2022.941832. PMID: 36387893Free PMC Article
Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy.
Ruttala HB, Ko YT
Pharm Res 2015 Mar;32(3):1002-16. Epub 2014 Sep 12 doi: 10.1007/s11095-014-1512-2. PMID: 25213777

Prognosis

Development of Preladenant-Based Radiotracers for Imaging A(2A)R in Tumors.
Zeng X, Liu H, Huang G, Wang Y, Zhou W, Wang Y, Chen X, Cheng X, Zhuang R, Li J, Fang J, Huang L, Zhang X, Guo Z
J Med Chem 2024 Aug 8;67(15):13056-13066. Epub 2024 Jul 22 doi: 10.1021/acs.jmedchem.4c01015. PMID: 39036887
Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, Miki M, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y
J Gastroenterol 2023 Jun;58(6):586-597. Epub 2023 Apr 26 doi: 10.1007/s00535-023-01987-8. PMID: 37099152
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E, Kjellman M, Knigge U, Gronbaek H, Schalin-Jäntti C, Welin S, Sorbye H, Del Pilar Schneider M, Belusa R; Nordic NET Biomarker Group
J Neuroendocrinol 2022 Jul;34(7):e13176. Epub 2022 Jul 13 doi: 10.1111/jne.13176. PMID: 35829662Free PMC Article
Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J, Bjellerup-Calissendorff F, Bränström R, Juhlin CC, Falhammar H
Front Endocrinol (Lausanne) 2021;12:657698. Epub 2021 Apr 13 doi: 10.3389/fendo.2021.657698. PMID: 33927695Free PMC Article
Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome.
Bogina G, Munari E, Brunelli M, Bortesi L, Marconi M, Sommaggio M, Lunardi G, Gori S, Massocco A, Pegoraro MC, Zamboni G
Histopathology 2016 Feb;68(3):422-32. Epub 2015 Aug 17 doi: 10.1111/his.12766. PMID: 26114478

Clinical prediction guides

TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING.
Bharti V, Kumar A, Wang Y, Roychowdhury N, de Lima Bellan D, Kassaye BB, Watkins R, Capece M, Chung CG, Hilinski G, Vilgelm AE
JCI Insight 2024 Jun 20;9(15) doi: 10.1172/jci.insight.177523. PMID: 38900577
Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2.
Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, Miki M, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y
J Gastroenterol 2023 Jun;58(6):586-597. Epub 2023 Apr 26 doi: 10.1007/s00535-023-01987-8. PMID: 37099152
Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcome.
Metovic J, Cascardi E, Uccella S, Maragliano R, Querzoli G, Osella-Abate S, Pittaro A, La Rosa S, Bogina G, Cassoni P, Marchiò C, Sapino A, Castellano I, Papotti M
Virchows Arch 2022 Dec;481(6):839-846. Epub 2022 Oct 15 doi: 10.1007/s00428-022-03426-0. PMID: 36243799Free PMC Article
Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.
Thiis-Evensen E, Kjellman M, Knigge U, Gronbaek H, Schalin-Jäntti C, Welin S, Sorbye H, Del Pilar Schneider M, Belusa R; Nordic NET Biomarker Group
J Neuroendocrinol 2022 Jul;34(7):e13176. Epub 2022 Jul 13 doi: 10.1111/jne.13176. PMID: 35829662Free PMC Article
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P, Slaninová I
Molecules 2019 Jun 7;24(11) doi: 10.3390/molecules24112152. PMID: 31181622Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    -